Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28556911 | 0.97 | LMNA (0.38) | LMNAF2SMN1; SMN2DPP7L3MBTL1 | |
| SCHEMBL4985800 | 0.97 | — | — | |
| Iodide SCHEMBL29124171 | 0.94 | LMNA (0.34) | LMNAF2 | |
| Sulfuric Acid SCHEMBL10736945 | 0.88 | BLM (0.42) | LMNAF2SMN1; SMN2DPP7L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6271047 | 0.74 | F2 (0.42) | LMNAF2DPP7 | |
| SCHEMBL2755822 | 0.73 | SMN1; SMN2 (0.37) | LMNASMN1; SMN2 | |
| SCHEMBL4984203 | 0.72 | FAAH (0.31) | — | |
| SCHEMBL3589175 | 0.72 | CA2 (0.31) | — | |
| SCHEMBL1713380 | 0.71 | F2 (0.30) | F2 | |
| SCHEMBL2950663 | 0.71 | SMN1; SMN2 (0.31) | F2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214314-B1 | AMINOPIPERIDINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2005-09-07 | — | — | EP | claimed |
| CN-105873982-B | Polyetherimide with improved melt stability | 沙特基础工业全球技术有限公司 | 2019-07-12 | — | — | CN | disclosed |
| CN-101360754-B | Process for producing mercaptoalkylalkoxysilanes | MOMENTIVE PERFORMANCE MAT INC | 2012-01-11 | — | — | CN | disclosed |
| US-7351743-B1 | Therapeutic guanidines | WYETH (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | SCION PHARMACEUTICALS, INC, A DELAWARE CORPORATION | 2007-11-15 | — | — | US | disclosed |
| EP-1083980-B1 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS INC (US) | 2007-03-21 | — | — | EP | disclosed |
| WO-2003091268-A1 | MOLECULAR INTERACTION SITES OF VIMENTIN RNA AND METHODS OF MODULATING THE SAME | ISIS PHARMACEUTICALS, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1060270-A4 | MASS SPECTROMETRIC METHODS FOR BIOMOLECULAR SCREENING | ISIS PHARMACEUTICALS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6288123-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | CAMBRIDGE NEUROSCIENCES, INC. | 2001-09-11 | — | — | US | disclosed |
| EP-1083980-A2 | MODULATION OF MOLECULAR INTERACTION SITES ON RNA AND OTHER BIOMOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999045150-A9 | MASS SPECTROMETRIC METHODS FOR BIOMOLECULAR SCREENING | ISIS PHARMACEUTICALS INC (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999045150-A1 | MASS SPECTROMETRIC METHODS FOR BIOMOLECULAR SCREENING | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| EP-0804431-A4 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0832879-A1 | Process for preparing intermediates for thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0804431-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| US-5610308-A | Process for preparing intermediates for thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| EP-0157762-B1 | NEW SUBSTITUTED PIPERIDINOGUANIDINES, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOUCHARA S.A. (FR) | 1990-08-08 | — | — | EP | disclosed |
| EP-0157762-A1 | NEW SUBSTITUTED PIPERIDINOGUANIDINES, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | BOUCHARA EMILE (FR) | 1985-10-16 | — | — | EP | disclosed |
| WO-1985001288-A1 | NEW SUBSTITUTED PIPERIDINOGUANIDINES, PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BOUCHARA, EMILE (FR) | 1985-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265348-A1 | N-(4-sec-butylphenyl)-N-benzylguanidine; modulate, particularly inhibit, the release of neurotransmitter such as glutamate; neurodegenerative disease: Parkinson's, Huntington's, Alzheimer's diseases, Amyotrophic Lateral Sclerosis, Down's Syndrome, epilepsy, atrophy, HIV | GAP43, NLN, HTT | LMNA 1216/4885F2 4870/4885SMN1; SMN2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.